In the Press
September 15, 2021

State Drug Transparency Laws: Considerations for Pharmaceutical Manufacturers (AHLA’s 2021 Health Law Watch)

Goodwin Healthcare associate Heath Ingram co-authored a chapter in the American Health Law Association’s latest Health Law Watch book. In their chapter, “State Drug Transparency Laws: Considerations for Pharmaceutical Manufacturers,” O’Rourke and Ingram provide a comprehensive overview of the evolution of state drug transparency laws and their enforcement, five frameworks manufacturers can follow to help comply with each state’s requirements, insights into the data and public reports produced under these laws, compliance strategies and tips for pharmaceutical companies, and upcoming drug pricing developments under the Biden administration’s healthcare plan.

To read the chapter, purchase the AHLA Health Law Watch.